Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (7860)	5/2/2000 12:44:00 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 8116

NEW YORK, March 21 /PRNewswire/ -- The following is being issued by OscarGruss & Son Incorporated, a member of the National Association of Securities Dealers, CRD number 2091: Oscar Gruss & Son has issued an in-depth biotechtechnology review entitled "Trends in Commercial Bioinformatics." Author Jason Reed, Ph.D., equity research analyst at Oscar Gruss, provides a detailed examination of the emerging commercial market for "bioinformatics technology" -- the computational tools, databases and information technology services that support genomic and related research. Dr. Reed believes that bioinformatics technology will become an increasingly important competitive differentiator for public and private life science companies going forward.By Dr. Reed's estimation, there are more than fifty companies that offer bioinformatics products and services of various kinds to external customers.In surveying the industry, he finds surging volume growth, particularly among leading companies, and an acceleration in the number of corporate deals and collaborations. Dr. Reed believes that this reflects the explosive growth in genomic and related research techniques, plus the weaknesses of available analysis tools and databases. Within five years, Dr. Reed projects that the total market for bioinformatics tool and services, including custom databases, could exceed $2.0 billion. Companies discussed in this report include: Agilent Technologies (NYSE: A) Celera Genomics (NYSE: CRA) Compaq (NYSE: CPQ) CuraGen (Nasdaq: CRGN) DoubleTwist.com GeneLogic (Nasdaq: GLGC) Genomica Human Genome Sciences (Nasdaq: HGSI) IBM (NYSE: IBM) Incyte Pharmaceuticals (Nasdaq: INCY) Informax (here is Cytogen) Lion Bioscience Myriad Genetics (Nasdaq: MYGN) Netgenics Oxford Molecular (London: OMG) PE Biosystems (NYSE: PEB) Rosetta Inpharmatics Spotfire Clients of Oscar Gruss wishing to get a copy of this report should contacttheir broker.